益气健脾补肾法对老年肌少症的临床疗效探索

注册号:

Registration number:

ChiCTR2300074970 

最近更新日期:

Date of Last Refreshed on:

2024-01-17 19:46:09 

注册时间:

Date of Registration:

2023-08-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

益气健脾补肾法对老年肌少症的临床疗效探索

Public title:

Study on the clinical effect of supplementing qi and invigorating spleen and tonifying kidney for senile sarcopenia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

益气健脾补肾法对老年肌少症的临床疗效探索

Scientific title:

Study on the clinical effect of supplementing qi and invigorating spleen and tonifying kidney for senile sarcopenia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴靓 

研究负责人:

吴靓 

Applicant:

Wu Liang 

Study leader:

Wu Liang 

申请注册联系人电话:

Applicant telephone:

+86 139 1727 4328

研究负责人电话:

Study leader's
telephone:

+86 139 1727 4328

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wuliang_sheshou1@126.com

研究负责人电子邮件:

Study leader's E-mail:

wuliang_sheshou1@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区四川北路1878号

研究负责人通讯地址:

上海市虹口区四川北路1878号

Applicant address:

1878 Sichuan Road North, Hongkou District, Shanghai

Study leader's address:

1878 Sichuan Road North, Hongkou District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市虹口区江湾医院

Applicant's institution:

Jiangwan Hospital, Hongkou District, Shanghai

研究负责人所在单位:

上海市虹口区江湾医院

Affiliation of the Leader:

Jiangwan Hospital, Hongkou District, Shanghai

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023第(001)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市虹口区江湾医院伦理委员会

Name of the ethic committee:

Ethics Committee of Jiangwan Hospital, Hongkou District, Shanghai

伦理委员会批准日期:

Date of approved by ethic committee:

2023-05-10 00:00:00

伦理委员会联系人:

罗振东

Contact Name of the ethic committee:

Luo Zhendong

伦理委员会联系地址:

上海市虹口区四川北路1878号

Contact Address of the ethic committee:

1878 Sichuan Road North, Hongkou District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 180 1730 0780

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市虹口区江湾医院

Primary sponsor:

Jiangwan Hospital, Hongkou District, Shanghai

研究实施负责(组长)单位地址:

上海市虹口区四川北路1878号

Primary sponsor's address:

1878 Sichuan Road North, Hongkou District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市虹口区江湾医院

具体地址:

上海市虹口区四川北路1878号

Institution
hospital:

Jiangwan Hospital, Hongkou District, Shanghai

Address:

1878 Sichuan Road North, Hongkou District, Shanghai

经费或物资来源:

虹口区卫健委和上海市虹口区江湾医院

Source(s) of funding:

Hongkou District Health Committee and Jiangwan Hospital

研究疾病:

肌少症  

Target disease:

Sarcopenia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

采用益气健脾补肾中药治疗老年肌少症,通过观察肌肉质量、肌肉力量、肌肉功能、炎症指标、营养状况、胰岛素抵抗、中医证候积分、生活质量的评价,研究脾肾同治法治疗老年肌少症的疗效。  

Objectives of Study:

To study the effect of spleen-kidney combination therapy on senile sarcopenia by observing muscle mass, muscle strength, muscle function, inflammatory indicators, nutritional status, insulin resistance, TCM syndrome score and quality of life.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并有其他的严重的器质性疾病,或者意识不清和认知功能低下的,或严重营养不良者; 2.急性丧失活动能力患者,如各种骨折导致活动能力降低者; 3.慢性消耗性疾病晚期患者,如恶性肿瘤晚期、慢性阻塞性肺病(COPD)、严重慢性肾病、严重糖尿病,或极度肥胖者; 4.神经肌肉疾病(如帕金森病),或其他肌萎缩、肌炎等肌肉系统障碍性疾病影响肌少症诊断指标者; 5.双下肢明显水肿者; 6.既往患有精神疾患、语言和情感表达交流障碍者; 7.体内装有心脏起搏器或者支架的人及装有金属内固定物者,但不包括假牙。

Exclusion criteria:

1. Combined with other serious organic diseases, or unconsciousness and cognitive impairment, or severe malnutrition; 2. Patients with acute disability, such as those with reduced mobility due to various fractures; 3. People with advanced chronic wasting diseases, such as cancer, chronic obstructive pulmonary disease (COPD), severe chronic kidney disease, severe diabetes, or extreme obesity; 4. Neuromuscular diseases (such as Parkinson's disease), or other muscular disorders such as muscular atrophy and myositis that affect the diagnostic indicators of sarcopenia; 5. Patients with obvious edema of both lower limbs; 6. People with mental illness, language and expressive communication disorders; 7. Persons with pacemakers or stents in their bodies and persons with metal internal fixators, but not dentures.

研究实施时间:

Study execute time:

From 2023-09-01 00:00:00 To 2025-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-09-01 00:00:00 To 2025-07-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

33

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

组别:

实验组

样本量:

33

Group:

Test group

Sample size:

干预措施:

服用益气健脾补肾的中药

干预措施代码:

Intervention:

Taking decoction to supplement qi and invigorate spleen and tonify kidney.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市虹口区江湾医院 

单位级别:

二级 

Institution
hospital:

Jiangwan Hospital, Hongkou District, Shanghai

Level of the institution:

Secondary

测量指标:

Outcomes:

指标中文名:

肌肉衰减症的生活质量量表

指标类型:

主要指标

Outcome:

sarcopenia quality of life

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

主要指标

Outcome:

TCM syndrome integral

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

小腿围测量

指标类型:

次要指标

Outcome:

Calf circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

四肢骨骼肌量

指标类型:

次要指标

Outcome:

Skeletal muscle mass

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

握力

指标类型:

次要指标

Outcome:

Grip strength

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

步速

指标类型:

次要指标

Outcome:

Pace

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

outine blood test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reaction protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清白蛋白

指标类型:

次要指标

Outcome:

Blood albumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

Fasting blood sugar

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血浆胰岛素

指标类型:

次要指标

Outcome:

Fasting plasma insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究人员按随机数字表法将66病例分为实验组33例,对照组33例。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the random number table method, 66 patients were divided into the test group (33 cases) and the control group (33 cases).

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向项目负责人申请,视情况进行数据分享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Apply to the project leader for data sharing as appropriate.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-22 09:42:50